is an associate in the Intellectual Property Department and member of the Chemical and Pharmaceutical practice teams in Ballard Spahr’s Patents Group. Clint’s practice focuses on drafting and prosecuting domestic and foreign patent applications, opinion work, client counseling, intellectual property litigation, and proceedings at the USPTO—including post-grant and inter partes review proceedings.
For more information or to contact Clint, please visit his Firm Profile Page.
With cannabis now legal in some form across more than 30 states, the cannabis industry is on the rise and expected to achieve a market size of more than $60 billion by the end of 2025. As with any new and growing industry, intellectual property protection will be central to innovation and investment. Several unique challenges emerge at the intersection of cannabis and intellectual property law, the first of which is obtaining protection for a cannabis-related business or invention. Two characteristics of cannabis make intellectual property protection challenging—its status as a Schedule I drug under the Controlled Substances Act and the fact that many cannabis species are naturally-occurring. Applications for cannabis trademarks, for instance, have encountered resistance at the U.S. Patent and Trademark Office (USPTO) due to cannabis’s illegal status under federal law. Unlike trademarks, however, a patent does not require an applicant to show that the product is lawfully used in interstate commerce. Rather, a patent provides the right to exclude others from the invention, and there is nothing unlawful about obtaining such a right.